<ѻý>TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progressionѻý> More than a fifth of patients responded to lenvatinib-pembrolizumab combination Jul 26, 2022
<ѻý>Sexual Dysfunction, Hair Loss Among Long COVID Symptomsѻý> Wider range of post-COVID symptoms emerge than previously thought Jul 25, 2022
<ѻý>A Monkeypox Momentѻý> Let's use the lessons we learned from COVID-19 to battle this new disease threat Jul 25, 2022
<ѻý>Dear Acne: You've Ruined My Life, I Hate Youѻý> Personifying acne, scarring provides new insight into psychosocial burden of condition Jul 22, 2022
<ѻý>Topical JAK Inhibitor OK'd for Repigmentation of Vitiligoѻý> Significantly more patients achieved 75%, 90% improvement Jul 19, 2022
<ѻý>Novel Nitric Oxide Gel Clears Kids' Molluscum Contagiosum Lesionsѻý> Children may not need to "wait it out" for much longer, positive trial suggests Jul 13, 2022
<ѻý>Make the Diagnosis: She’s Too Young for Lines on Her Faceѻý> A 9-year-old girl was brought to the doctor by her mother after noticing a rash that had developed on the girl's face over the past week. Jul 13, 2022
<ѻý>Chronic, Disfiguring Facial Rash With No Itching or Painѻý> Female patient reports low quality of life after 10 years of treatments with no response Jul 11, 2022
<ѻý>Odevixibat Scratches the Itch of Kids' Rare Liver Diseaseѻý> Phase III trial showed reduced pruritus in progressive familial intrahepatic cholestasis Jul 08, 2022
<ѻý>Which Biologics Stick Longest for Psoriasis?ѻý> British data highlight factors affecting drug longevity Jul 06, 2022
<ѻý>Does Sunlight Trigger Lupus?ѻý> Analysis of data from major study suggests "yes," but falls short of clear conclusion Jun 22, 2022
<ѻý>Health Equity, Gun Violence Prevention Among Priorities for AMA's New Presidentѻý> Jack Resneck, Jr., MD, talks about running "the race we're in" Jun 15, 2022
<ѻý>FDA Approves First Systemic Treatment for Alopecia Areataѻý> Four to 10 times as many patients met hair-regrowth endpoint with JAK inhibitor versus placebo Jun 13, 2022
<ѻý>Something Fishy About Tuna and Melanoma Riskѻý> Higher total fish intake linked with 22% higher risk of malignant tumors Jun 09, 2022
<ѻý>Novel IL-17 Inhibitor Passes Mid-Stage Test in Psoriatic Arthritisѻý> Phase II results suggest drug could outperform existing agents Jun 03, 2022
<ѻý>Why the Atypical Symptoms in the Latest Monkeypox Cases?ѻý> Experts agree these cases are unusual, but not necessarily a concern for viral mutation May 27, 2022
<ѻý>Lance Bass' Psoriatic Arthritisѻý> "I just figured it was because of dancing," says former member of 'NSYNC May 26, 2022
<ѻý>FDA OKs First Novel Nonsteroidal Topical for Plaque Psoriasis in 25 Yearsѻý> Complete, near-complete clearance in 35-40% of patients treated with tapinarof cream 1% May 24, 2022
<ѻý>Oral Retinoid May Ease Painful Skin Reactions to Anticancer Therapyѻý> Preliminary data on acitretin therapy are promising May 11, 2022
<ѻý>In Lupus, 'Normal-Appearing' Skin Is Not Normalѻý> Groundwork for inflammation laid before lesions develop Apr 27, 2022
<ѻý>Testing for Th/To Antibodies May Help in Scleroderma Managementѻý> Test identifies patients at high risk for pulmonary hypertension Apr 25, 2022
<ѻý>FDA OKs New Topical for Inflammatory Rosaceaѻý> Almost half of patients clear of lesions or nearly so with benzoyl peroxide 5% cream (Epsolay) Apr 25, 2022
<ѻý>Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1ѻý> But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
<ѻý>Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1ѻý> Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
<ѻý>Response in Kids With Psoriasis Maintained Long Term With IL-17A Inhibitorѻý> At least 75% improvement at 108 weeks in patients treated with ixekizumab Apr 13, 2022
<ѻý>Smoker's Painless Skin Nodules Flag a Fatal Diagnosisѻý> Skin metastasis was the first sign for the otherwise asymptomatic patient Apr 04, 2022
<ѻý>First Topical Therapy for Facial Angiofibroma Nabs FDA Approvalѻý> New alternative to dermabrasion, laser treatment, surgery Apr 04, 2022
<ѻý>Chronic Spontaneous Urticaria Responds Quickly to BTK Inhibitorѻý> AAD data also promising for therapies in psoriasis, pyoderma gangrenosum Mar 31, 2022
<ѻý>Psoriasis Therapy Has Mixed Effects on Cardiovascular Risk Factorsѻý> No reduction in vascular inflammation with apremilast but significant reduction in body fat Mar 30, 2022
<ѻý>Meta-Analysis of Atopic Dermatitis Drugs Favors Two JAK Inhibitorsѻý> Small advantages for abrocitinib, upadacitinib, but data still accumulating for all the players Mar 30, 2022
<ѻý>Toward More Uniform Methotrexate Dosing in Psoriasisѻý> International expert group urges common standards Mar 30, 2022
<ѻý>Jada Pinkett Smith's Alopeciaѻý> The condition at the center of this year's Academy Awards drama Mar 29, 2022
<ѻý>Significant Improvement in Vitiligo With JAK Inhibitor Therapyѻý> Durable improvement in pigmentation with topical ruxolitinib, oral ritlecitinib Mar 29, 2022
<ѻý>Atopic Dermatitis: Promising Data for New Mechanistic Approachѻý> Rapid responses in a majority of patients in small trial of eblasakimab Mar 28, 2022
<ѻý>Targeted Antibody Provides Significant Relief From Itchy Nodular Conditionѻý> Dupilumab reduces itch, lesion count in first phase III trial for prurigo nodularis Mar 28, 2022
<ѻý>Dramatic, Durable Hair Growth With Oral JAK Inhibitorѻý> Oral baricitinib superior to placebo at 36 weeks in BRAVE-AA1 and BRAVE-AA2 trials Mar 27, 2022
<ѻý>Novel Fixed-Dose Immunotherapy Combo Wins FDA Approvalѻý> Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
<ѻý>Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancerѻý> Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
<ѻý>Clinic-Based Hidradenitis Suppurativa Surgery Gets High Marks From Patientsѻý> High satisfaction after three-fourths of procedures, despite frequent recurrences Mar 17, 2022
<ѻý>Extension Study Confirms JAK Inhibitor's Activity in Atopic Dermatitisѻý> EASI75 response rate exceeding 80% through 52 weeks of upadacitinib treatment Mar 16, 2022